Drug Profile
RN 564
Alternative Names: RN564Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Osteoporosis therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Osteoporosis in USA (IV, Infusion)
- 31 May 2012 Pfizer completes a phase I trial in Osteoporosis in USA (NCT01293487)